| Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ... PloS one 11 (6), e0157368, 2016 | 1272 | 2016 |
| Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ... Genome medicine 11, 1-20, 2019 | 891 | 2019 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 677 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 605 | 2017 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 530 | 2016 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 507 | 2016 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 506 | 2017 |
| A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ... Clinical cancer research 23 (1), 26-34, 2017 | 338 | 2017 |
| Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer VM Jansen, NE Bhola, JA Bauer, L Formisano, KM Lee, KE Hutchinson, ... Cancer research 77 (9), 2488-2499, 2017 | 217 | 2017 |
| Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, ... The Lancet Oncology 22 (6), 883-892, 2021 | 144 | 2021 |
| Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, ... Science translational medicine 8 (334), 334ra53-334ra53, 2016 | 140 | 2016 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ... JCI insight 3 (24), 2018 | 138 | 2018 |
| A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and … B Jovanović, IA Mayer, EL Mayer, VG Abramson, A Bardia, ME Sanders, ... Clinical Cancer Research 23 (15), 4035-4045, 2017 | 128 | 2017 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 126 | 2017 |
| Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ... Science translational medicine 9 (402), eaai7993, 2017 | 121 | 2017 |
| The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation DP Kodack, V Askoxylakis, GB Ferraro, Q Sheng, M Badeaux, S Goel, ... Science translational medicine 9 (391), eaal4682, 2017 | 102 | 2017 |
| Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers M Morrison Joly, DJ Hicks, B Jones, V Sanchez, MV Estrada, C Young, ... Cancer research 76 (16), 4752-4764, 2016 | 102 | 2016 |
| Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer AB Hanker, MV Estrada, G Bianchini, PD Moore, J Zhao, F Cheng, ... Cancer research 77 (12), 3280-3292, 2017 | 92 | 2017 |
| HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2 AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ... Clinical Cancer Research 23 (15), 4323-4334, 2017 | 81 | 2017 |
| Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 BN Rexer, R Ghosh, A Narasanna, MV Estrada, A Chakrabarty, Y Song, ... Clinical Cancer Research 19 (19), 5390-5401, 2013 | 81 | 2013 |
